Fig. 4From: Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trialsForest plots of serious adverse events comparing tocilizumab combination therapy (TCZ COMBI ) with tocilizumab monotherapy (TCZ MONO ) (a), TCZ COMBI with a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) (b) and TCZMONO with a csDMARD (c)Back to article page